Cyclophosphamide

證據等級: L5

預測適應症: 5 個

Cyclophosphamide: From Broad-Spectrum Alkylating Chemotherapy to Myeloid Leukemia

One-Sentence Summary

Cyclophosphamide is a classical nitrogen mustard alkylating agent used globally across oncology and immunology settings, though it holds no current SFDA registration in Saudi Arabia. The TxGNN model predicts it may be particularly effective for Myeloid Leukemia — spanning both myeloablative conditioning for allogeneic HSCT and post-transplant GVHD prevention — with multiple completed Phase 2/3 clinical trials and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	No SFDA-approved indication on record (not currently marketed in Saudi Arabia)
Predicted New Indication	Myeloid Leukemia
TxGNN Prediction Score	99.47%
Evidence Level	L2
Saudi Arabia Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the DrugBank record retrieved for this analysis. Based on known clinical information, cyclophosphamide is an alkylating agent (nitrogen mustard class) whose active metabolites — primarily 4-hydroxycyclophosphamide and phosphoramide mustard — form DNA inter- and intra-strand crosslinks, triggering apoptosis in rapidly proliferating cells such as leukemic blasts. At myeloablative doses it eliminates residual disease and creates marrow space for donor engraftment; at lower doses it selectively depletes proliferating alloreactive T cells while sparing quiescent regulatory T cells (Tregs).

Myeloid leukemia involves clonal expansion of malignant myeloid progenitors in the bone marrow. Cyclophosphamide's myeloablative properties have made it a cornerstone of conditioning regimens for allogeneic HSCT in AML: the BuCy (busulfan + cyclophosphamide) protocol has been a reference-standard myeloablative conditioning regimen for decades, and remains in active use as shown by Phase 3 data (NCT01191957, n=252). A completed Phase 3 trial also demonstrated its role in high-dose intensification prior to autologous SCT in adult myeloid leukemia (NCT00002945).

A second, more contemporary mechanistic rationale centers on post-transplant cyclophosphamide (PTCy): administered at 50 mg/kg on days +3 and +4 following allo-HSCT, PTCy eliminates alloreactive T cells that have proliferated in response to donor-host MHC mismatches, thereby preventing graft-versus-host disease (GVHD) while preserving graft-versus-leukemia (GVL) activity. PTCy has emerged as the preferred GVHD prophylaxis strategy across haploidentical, matched-related, and matched-unrelated donor settings in AML, accumulating registry-level cohort evidence exceeding 1,800 patients (PMID 39939431). The TxGNN prediction is therefore strongly supported by both mechanistic plausibility and clinical validation.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01191957	Phase 3	Completed	252	Prospective randomized comparison of IV BuFlu vs BuCy2 as conditioning for AML patients ≥40 years in complete remission undergoing allo-HSCT; primary endpoints transplant-related mortality at 1 year and anti-leukemic efficacy — the pivotal dataset for Cy-based conditioning in older AML
NCT00002945	Phase 3	Completed	61	High-dose cytarabine + idarubicin induction followed by high-dose etoposide + cyclophosphamide intensification, autologous SCT, and IL-2 immune modulation in previously untreated adult myeloid leukemia; evaluates Cy as a key intensification component
NCT00003868	Phase 2	Completed	40	Radiolabeled BC8 (anti-CD45) antibody combined with cyclophosphamide and TBI followed by HLA-matched related or unrelated HSCT in advanced AML and MDS; directly tests Cy as part of targeted radioimmuno-conditioning, with long-term survival data
NCT00005892	N/A	Completed	N/A	Moderate-dose cyclophosphamide plus radiotherapy before allogeneic BMT in AML and MDS related to Fanconi's anemia; determines whether dose-attenuated Cy-containing conditioning can reduce morbidity while maintaining efficacy
NCT07108530	Phase 2	Recruiting	50	Multicenter single-arm study evaluating an integrated induction-consolidation-transplantation protocol in adult AML (excluding M3 subtype); two modern induction options (IAV and DAV regimens), representing current standard-of-care transplant trajectory
NCT03602898	Phase 2	Withdrawn	0	Randomized design comparing ATG vs post-transplant cyclophosphamide (PTCy) vs calcineurin inhibitor + methotrexate as GVHD prophylaxis after myeloablative unrelated donor PBSC transplantation; withdrawn before enrolment, but the scientific question remains clinically active and unanswered
NCT00309842	Phase 2	Completed	213	Cyclophosphamide/fludarabine/TBI myeloablative preparative regimen for unrelated umbilical cord blood transplantation in hematological malignancies including myeloid leukemia; largest UCB-conditioning dataset with explicit Cy dosing
NCT00852709	Phase 1	Terminated	35	Dose-escalation study of clofarabine followed by escalating fractionated cyclophosphamide in children with relapsed or refractory acute leukemias; provides MTD and safety data for Cy in the pediatric leukemia context
NCT01338987	Phase 2	Completed	76	Lupron to enhance lymphocyte immune reconstitution following allogeneic BMT (Cy as preparative regimen component); 9-year enrolment period with molecular imaging evaluation, offering long-term safety and immune reconstitution data
NCT04835519	Phase 1/2	Completed	5	CD33 CAR-T cells in relapsed/refractory AML; cyclophosphamide (250 mg/m²) used as lymphodepletion pretreatment alongside fludarabine, confirming its enabling role for next-generation cellular immunotherapy in AML

Literature Evidence

PMID	Year	Type	Journal	Key Findings
36357773	2023	Systematic Review / NMA	Bone Marrow Transplantation	Bayesian network meta-analysis of myeloablative conditioning regimens for AML undergoing allo-HSCT in complete remission; Bu/Cy (oral 16 mg/kg or IV 12.8 mg/kg) benchmarked against all major alternatives — defines relative efficacy and toxicity positioning
39939431	2025	Retrospective Cohort	Bone Marrow Transplantation	1,823 AML patients in CR1 receiving first allo-HSCT with PTCy; analyzed impact of conditioning intensity stratified by cytogenetic/molecular risk — largest published PTCy dataset in AML to date
40905088	2026	Cohort / Registry	Haematologica	217 AML patients receiving MAC + PTCy-based GVHD prophylaxis; 2-year OS 77%, EFS 72%; assesses prognostic significance of ELN 2022 genetic risk categories in the PTCy era
40437709	2025	Retrospective Cohort	European Journal of Haematology	MAC vs RIC conditioning in AML patients <65 years receiving ATG + PTCy-based GVHD prophylaxis; demonstrates that conditioning intensity modulation within a PTCy backbone impacts disease control without proportional toxicity increase
38499049	2024	Prospective Phase 2	Transplant Immunology	Cladribine + BuCy as intensive conditioning prior to allo-HSCT in relapsed/refractory AML; directly evaluates an augmented Cy-containing conditioning regimen for the most difficult-to-treat AML patients
40434956	2025	Retrospective Cohort	Future Oncology	Head-to-head comparison of BuCy vs FluBu myeloablative conditioning for allo-HSCT in AML; confirms BuCy as an active comparator with similar efficacy and a distinct toxicity profile
38466265	2024	Retrospective Cohort	Cytotherapy	Prognostic factors in haploidentical HSCT with PTCy for AML; identifies disease status, donor-recipient CMV serostatus, and conditioning intensity as key outcome predictors in the PTCy paradigm
32428903	2021	Retrospective Cohort	Acta Haematologica	PTCy (50 mg/kg, days +3/+4) + ATG (4.5 mg/kg) as GVHD prophylaxis for high-risk AML and MDS undergoing allo-HCT; compared to alternative prophylaxis regimens, demonstrating the combination's feasibility in very high-risk disease
33325761	2021	Retrospective Series	Leukemia & Lymphoma	High-dose cyclophosphamide (HDCy, 60 mg/kg) as emergency cytoreduction in 27 AML patients with hyperleukocytosis or leukostasis; demonstrates direct anti-leukemic efficacy outside the transplant setting
35955881	2022	Retrospective Cohort	Int'l J Molecular Sciences	PTCy as GVHD prophylaxis in pediatric AML after matched related and unrelated donor HSCT; first published pediatric AML dataset in this context, addressing an important gap in the evidence base

Saudi Arabia Market Information

Cyclophosphamide is currently not registered with the Saudi Food and Drug Authority (SFDA). No product licenses, approved dosage forms, or approved indications are on record. Formal market authorization would be required before clinical use under Saudi Arabia regulatory jurisdiction.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (Nitrogen mustard alkylating agent)
Myelosuppression Risk	High — leukopenia, thrombocytopenia, and anemia are expected dose-dependent effects; nadir typically occurs 8–14 days post-administration; high-dose regimens used in AML conditioning carry severe myeloablation by design
Emetogenicity Classification	Moderate (standard doses) to High (high-dose conditioning ≥600 mg/m²); prophylactic anti-emetic regimens including NK1-receptor antagonists are required at conditioning doses
Monitoring Items	CBC with differential (daily during conditioning, then per protocol), serum creatinine and LFTs, urinalysis and urine microscopy (hemorrhagic cystitis surveillance), electrolytes, and SIADH monitoring at high doses
Handling Protection	Required — cytotoxic drug handling protocols mandatory, including closed-system drug transfer devices, biological safety cabinet preparation, and appropriate PPE

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Cyclophosphamide's role in myeloid leukemia is supported by decades of clinical evidence, including completed Phase 3 randomized trials of BuCy conditioning in AML (n=252), prospective Phase 2 data in relapsed/refractory AML, and registry-scale retrospective cohorts encompassing over 1,800 AML patients receiving PTCy-based GVHD prophylaxis. The mechanistic rationale — myeloablation of leukemic blasts and selective elimination of alloreactive T cells — is well-characterized in the transplant literature. The TxGNN prediction at 99.47% is consistent with this established body of evidence.

To proceed, the following is needed:

Saudi Arabia SFDA registration pathway assessment and market access strategy for an unregistered cytotoxic agent
Formal package insert (SmPC) retrieval to document official warnings, contraindications, and drug-drug interactions
DrugBank MOA record completion to support regulatory submission documentation
Mesna co-administration protocol specification for hemorrhagic cystitis prevention in high-dose conditioning regimens
Mapping to local Saudi Arabia AML transplant practice guidelines to identify the specific clinical niche (BuCy conditioning vs. PTCy GVHD prophylaxis) where registration adds greatest value
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.